Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Dyne Therapeutics, Inc.

< Previous 1 2 Next >
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Announces CEO Transition
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at February Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at November Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at October Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at Jefferies Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Tickers DYN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.